A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria
Phase 3
Recruiting
- Conditions
- IgA Nephropathy (IgAN)
- Interventions
- Drug: SC0062 strength 10mgDrug: Placebo matched to SC0062
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06819826
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Yuexiu District, China
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 148
- Registration Number
- NCT06548672
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: BC3402 injection
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT06111326
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, China
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Phase 1
Not yet recruiting
- Conditions
- Advanced Ovarian CancerSerous Ovarian Cancer
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06055348
Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML
Phase 1
Recruiting
- Conditions
- Chronic Myelomonocytic LeukemiaMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT05970822
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT05957471
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-07-14
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 67
- Registration Number
- NCT05731518
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Phase I Study of BC3402 as a Single Agent in Patients With MDS and CMML
Phase 1
Recruiting
- Conditions
- Hematologic Malignancy
- Interventions
- Drug: BC3402 Injection
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT05690425
- Locations
- 🇨🇳
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Phase 2
Active, not recruiting
- Conditions
- Diabetic Kidney DiseaseIgA Nephropathy
- Interventions
- Drug: SC0062 high doseDrug: Placebo of SC0062Drug: SC0062 low doseDrug: SC0062 medium dose
- First Posted Date
- 2023-01-18
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT05687890
- Locations
- 🇨🇳
79 Qingchun Rd.,Shangcheng District, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath